All accepted abstracts, including Late-breaking, will be published online in the ESMO Breast Cancer 2025 Abstract Book, a supplement to the official ESMO journal,ESMO Open. Publication schedule of accepted abstracts Abstracts accepted for presentation during the ESMO Breast Cancer 2025 will be released...
*Abstracts may also be submitted to the Cancer nursing track. Submissions in these categories will be reviewed by the European Oncology Nursing Society (EONS) Scientific Committee for selection and presentation in the EONS cancer nursing programme. Unless otherwise stated, submissions in the Cancer nur...
*Abstracts may also be submitted to the Cancer nursing track. Submissions in these categories will be reviewed by the European Oncology Nursing Society (EONS) Scientific Committee for selection and presentation in the EONS cancer nursing programme. Unless otherwise stated, submissions in the Cancer nur...
Abstracts will be assessed for presentation at the Conference, either oral or poster, or for publication in the ABC7 Abstract Book, supplement ofThe Breast. The best abstracts will be selected for oral presentation within the programme with a 10-minute slide presentation followed by a 5-minute ...
Proffered Paper session:Breast cancer, early stage Educational session:Optimising overall survival in advanced renal cancer Educational session:Therapeutic view on tumour immune microenvironment: It's TIME Educational session:First-line therapy in ...
LBA13 - Dostarlimab + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Asian Subgroup Analyses of the PERLA Trial 参考文献: 1. https://www.esmo.org/meeting-calendar/esmo-asia-congress-...
The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes. The aim of this work is to organise health interventions for breast cancer management and research in ...
oncology pipelines and portfolios in the industry, Roche presentations include late-breaking abstracts featuring data in early-stage breast cancer and early-stage lung cancer, and a presentation on cancer of unknown primary (CUP), which has been selected for inclusion in the ESMO Press Programme. ...
(Rhizen), a Switzerland-based privately held, clinical-stage biopharmaceutical company announced today that it is presenting promising interim data from an ongoing Ph2 trial of Tenalisib in locally advanced or metastatic breast cancer patients, at the ESMO Breast Cancer Meeting, in Berlin, Germany ...
7.Recent developments and translational aspects in targeted therapy for metastatic breast cancer 机译:转移性乳腺癌靶向治疗的最新进展和翻译方面 作者:Maximilian Marhold;Rupert Bartsch;Christoph Zielinski 期刊名称:《ESMO Open》|2016年第3期 关键词: ...